Disease · MONDO_0004970
Comparisons in its trials20
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 20
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel: deaths from any cause | 107 of 652 | 77 of 655 | 1,307 | NCT00805194 | Trial comparisons |
| Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel: serious adverse events | 224 of 652 | 206 of 655 | 1,307 | NCT00805194 | Trial comparisons |
| Figitumumab 20 mg/kg vs Figitumumab 30 mg/kg: serious adverse events | 56 of 85 | 53 of 83 | 168 | NCT00560560 | Trial comparisons |
| Arm A (Experimental): MM-121 in Combination With Docetaxel vs Arm B (Comparator): Docetaxel Alone: deaths from any cause | 64 of 103 | 25 of 49 | 152 | NCT02387216 | Trial comparisons |
| Arm A (Experimental): MM-121 in Combination With Docetaxel vs Arm B (Comparator): Docetaxel Alone: serious adverse events | 40 of 103 | 15 of 49 | 152 | NCT02387216 | Trial comparisons |
| Group 1 vs Group 2: serious adverse events | 30 of 72 | 20 of 65 | 137 | NCT00573131 | Trial comparisons |
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab vs ECX Only: serious adverse events | 0 of 35 | 0 of 36 | 71 | NCT00215644 | Trial comparisons |
| Arm A vs Arm B: deaths from any cause | 4 of 19 | 2 of 17 | 36 | NCT03738228 | Trial comparisons |
| Arm A vs Arm B: serious adverse events | 6 of 19 | 7 of 17 | 36 | NCT03738228 | Trial comparisons |
| Run-in Portion: PEGCISGEM vs Run-in Portion: PEGCISGEMATEZO: Run-in Portion: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters (Hematology and Blood Chemistry) | 0 of 9 | 0 of 9 | 18 | NCT03267940 | Trial comparisons |
| Run-in Portion: PEGCISGEM vs Run-in Portion: PEGCISGEMATEZO: Run-in Portion: Number of Participants With AEs Leading to Dose Reduction or Interruption of Any Study Medication | 6 of 9 | 7 of 9 | 18 | NCT03267940 | Trial comparisons |
| Run-in Portion: PEGCISGEM vs Run-in Portion: PEGCISGEMATEZO: Run-in Portion: Number of Participants With Adverse Events (AEs) | 9 of 9 | 9 of 9 | 18 | NCT03267940 | Trial comparisons |
| Nintedanib vs Placebo: serious adverse events | 3 of 6 | 3 of 6 | 12 | NCT02231164 | Trial comparisons |
| Group 1 - Metformin vs Group 2 - No Treatment: deaths from any cause | 0 of 6 | 0 of 4 | 10 | NCT01877564 | Trial comparisons |
| Group 1 - Metformin vs Group 2 - No Treatment: serious adverse events | 0 of 6 | 0 of 4 | 10 | NCT01877564 | Trial comparisons |
| Dose Level 1 vs Dose Level -1: Number of Adverse Events | 2 of 3 | 1 of 6 | 9 | NCT01679405 | Trial comparisons |
| Dose Level 1 vs Dose Level -1: deaths from any cause | 2 of 3 | 5 of 6 | 9 | NCT01679405 | Trial comparisons |
| Dose Level 1 vs Dose Level -1: serious adverse events | 2 of 3 | 5 of 6 | 9 | NCT01679405 | Trial comparisons |
| Dose Level 1 vs Dose Level -1: Objective Response Rate | 0 of 2 | 0 of 6 | 8 | NCT01679405 | Trial comparisons |
| Dose Level 1 vs Dose Level -1: Tumor Control Rate | 0 of 2 | 4 of 6 | 8 | NCT01679405 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004970/comparisons